Literature DB >> 16007203

Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF.

Claus Christensen1, Per Guldberg.   

Abstract

Constitutive activation of the RAS-RAF-MEK-ERK signaling cascade is a hallmark of cutaneous malignant melanoma. A single activating mutation (c.1799 T>A; p.V 600 E) in the gene encoding the serine/threonine kinase B-RAF occurs in >60% of the tumors. Previous work has shown that knockdown of (V 600 E)B-RAF by RNA interference induces a variety of phenotypic changes in cultured melanoma cells, including lower proliferation rates, reduced anchorage-independent growth and apoptosis. Here, we show that the majority of melanomas harboring the (V 600 E)B-RAF mutation have retained the wild-type (WT) B-RAF allele, and that these cells can be rescued from the effects of (V 600 E)B-RAF knockdown by stimulation with growth factors. Ectopic expression of short hairpin RNAs specifically suppressing (V 600 E)B-RAF in melanoma cell lines reduced colony formation by approximately 80%. This response could be rescued by basic fibroblast growth factor, hepatocyte growth factor or, to a lesser extent, endothelin-1. Rescue with growth factors was not possible in cell lines lacking (WT)B-RAF. Single-cell clones with efficient knockdown of (V 600 E)B-RAF could be propagated in the presence of basic fibroblast growth factor but underwent apoptosis or senescence-like growth arrest upon withdrawal of this growth factor. The ability of growth factors to modulate the response of (V 600 E)B-RAF knockdown in melanoma cells may have both experimental and therapeutic implications. Oncogene (2005) 24, 6292-6302.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16007203     DOI: 10.1038/sj.onc.1208758

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  19 in total

1.  Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.

Authors:  William D Tap; Ke-Wei Gong; Judy Dering; Yiou Tseng; Charles Ginther; Giovanni Pauletti; John A Glaspy; Richard Essner; Gideon Bollag; Peter Hirth; Chao Zhang; Dennis J Slamon
Journal:  Neoplasia       Date:  2010-08       Impact factor: 5.715

2.  The helicase HAGE expressed by malignant melanoma-initiating cells is required for tumor cell proliferation in vivo.

Authors:  Adam J Linley; Morgan G Mathieu; Amanda K Miles; Robert C Rees; Stephanie E B McArdle; Tarik Regad
Journal:  J Biol Chem       Date:  2012-03-05       Impact factor: 5.157

Review 3.  Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies.

Authors:  Ragini Kudchadkar; Kim H T Paraiso; Keiran S M Smalley
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

4.  Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

Authors:  Mitchell Cheung; Arati Sharma; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

5.  Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

Authors:  K H T Paraiso; I V Fedorenko; L P Cantini; A C Munko; M Hall; V K Sondak; J L Messina; K T Flaherty; K S M Smalley
Journal:  Br J Cancer       Date:  2010-06-08       Impact factor: 7.640

6.  Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.

Authors:  Anton Platz; Suzanne Egyhazi; Ulrik Ringborg; Johan Hansson
Journal:  Mol Oncol       Date:  2007-12-28       Impact factor: 6.603

7.  Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development.

Authors:  Melissa A Tran; Raghavendra Gowda; Arati Sharma; Eun-Joo Park; James Adair; Mark Kester; Nadine Barrie Smith; Gavin P Robertson
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

Review 8.  Melanoma biology and the promise of zebrafish.

Authors:  Craig J Ceol; Yariv Houvras; Richard M White; Leonard I Zon
Journal:  Zebrafish       Date:  2008-12       Impact factor: 1.985

Review 9.  Developmental pathways activated in melanocytes and melanoma.

Authors:  Jianglan Liu; Mizuho Fukunaga-Kalabis; Ling Li; Meenhard Herlyn
Journal:  Arch Biochem Biophys       Date:  2014-08-08       Impact factor: 4.013

10.  Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.

Authors:  Ana Preto; Joana Gonçalves; Ana P Rebocho; Joana Figueiredo; Ana M Meireles; Ana S Rocha; Helena M Vasconcelos; Hugo Seca; Raquel Seruca; Paula Soares; Manuel Sobrinho-Simões
Journal:  BMC Cancer       Date:  2009-10-31       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.